For the moment, the European Commission has not renewed its contract for the anti-Covid vaccines developed by AstraZeneca beyond the expiry of the current contract, scheduled for the end of June. This was stated by European Internal Trade Commissioner Thierry Breton on France Inter. “We have not renewed the order after June – he stressed -. We’ll see what happens”.
The European Commission last month filed a lawsuit against AstraZeneca for failing to comply with the contract to supply COVID-19 vaccines and for not having a “reliable” plan to ensure timely deliveries.
Speaking to France Inter, Breton did not express criticism of the AstraZeneca vaccine, which he instead defined as “a very interesting and very good vaccine“, especially “for the logistical conditions and temperatures” in which it can be stored. Now, however, Breton stressed, “we have started working with Pfizer with the second phase and second generation vaccines“.
The Anglo-Swedish company has repeatedly reduced supplies to European countries citing problems in production processes. So far it has delivered 6.5 million doses to Italy compared to almost 18 million Pfizer-BioNTech.
The AstraZeneca vaccine has also had several stops in Europe due to very rare cases of thrombosis. The decision not to renew the contract, however, has nothing to do with this and is only linked to the issue of non-respected deliveries.